Standard

The global prevalence of autism spectrum disorder: A three-level meta-analysis. / Таланцева, Оксана Игоревна; Романова, Раиса; Шурдова, Екатерина Михайловна; Долгорукова, Татьяна Александровна; Сологуб, Полина Сергеевна; Титова, Ольга Сергеевна; Клеева, Дария Федоровна; Григоренко, Елена Леонидовна.

In: Frontiers in Psychiatry, Vol. 14, 1071181, 09.02.2023.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Таланцева ОИ, Романова Р, Шурдова ЕМ, Долгорукова ТА, Сологуб ПС, Титова ОС et al. The global prevalence of autism spectrum disorder: A three-level meta-analysis. Frontiers in Psychiatry. 2023 Feb 9;14. 1071181. https://doi.org/10.3389/fpsyt.2023.1071181

Author

Таланцева, Оксана Игоревна ; Романова, Раиса ; Шурдова, Екатерина Михайловна ; Долгорукова, Татьяна Александровна ; Сологуб, Полина Сергеевна ; Титова, Ольга Сергеевна ; Клеева, Дария Федоровна ; Григоренко, Елена Леонидовна. / The global prevalence of autism spectrum disorder: A three-level meta-analysis. In: Frontiers in Psychiatry. 2023 ; Vol. 14.

BibTeX

@article{1937a90b70514ee39493ccbbde45142d,
title = "The global prevalence of autism spectrum disorder: A three-level meta-analysis",
abstract = "Autism spectrum disorder (ASD) is one the most disabling developmental disorders, imposing an extremely high economic burden. Obtaining as accurate prevalence estimates as possible is crucial to guide governments in planning policies for identification and intervention for individuals with ASD and their relatives. The precision of prevalence estimates can be heightened by summative analyses of the data collected around the world. To that end, we conducted a three-level mixed-effects meta-analysis. A systematic search of the Web of Science, PubMed, EMBASE, and PsycINFO databases from 2000 up to 13 July 2020 was performed, and reference lists of previous reviews and existing databases of prevalence studies were screened. Overall, 79 studies were included in the analysis of ASD and 59–in the analysis of previously existing relevant diagnoses: 30 for Autistic Disorder (AD), 15 for Asperger Syndrome (AS), and 14 for Atypical Autism (AA) and Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS); these research reports covered the period from 1994 to 2019. Pooled prevalence estimates were 0.72% (95% CI = 0.61–0.85) for ASD, 0.25% (95% CI = 0.18–0.33) for AD, 0.13% (95% CI = 0.07–0.20) for AS, and 0.18% (95% CI = 0.10–0.28) for the combined group of AA and PDD-NOS. Estimates were higher (1) for the studies that used records-review surveillance rather than other designs; (2) in North America compared with other geographical regions; and (3) in high-income compared with lower-income countries. The highest prevalence estimates were registered in the USA. There was an increase in autism prevalence estimates over time. The prevalence was also significantly higher for children aged between 6 and 12 years compared to children under the age of 5 and over the age of 13 years.",
keywords = "autism, prevalence, epidemiology, meta-analysis, systematic review, autism, epidemiology, meta-analysis, prevalence, systematic review",
author = "Таланцева, {Оксана Игоревна} and Раиса Романова and Шурдова, {Екатерина Михайловна} and Долгорукова, {Татьяна Александровна} and Сологуб, {Полина Сергеевна} and Титова, {Ольга Сергеевна} and Клеева, {Дария Федоровна} and Григоренко, {Елена Леонидовна}",
year = "2023",
month = feb,
day = "9",
doi = "10.3389/fpsyt.2023.1071181",
language = "English",
volume = "14",
journal = "Frontiers in Psychiatry",
issn = "1664-0640",
publisher = "Frontiers Media S.A.",

}

RIS

TY - JOUR

T1 - The global prevalence of autism spectrum disorder: A three-level meta-analysis

AU - Таланцева, Оксана Игоревна

AU - Романова, Раиса

AU - Шурдова, Екатерина Михайловна

AU - Долгорукова, Татьяна Александровна

AU - Сологуб, Полина Сергеевна

AU - Титова, Ольга Сергеевна

AU - Клеева, Дария Федоровна

AU - Григоренко, Елена Леонидовна

PY - 2023/2/9

Y1 - 2023/2/9

N2 - Autism spectrum disorder (ASD) is one the most disabling developmental disorders, imposing an extremely high economic burden. Obtaining as accurate prevalence estimates as possible is crucial to guide governments in planning policies for identification and intervention for individuals with ASD and their relatives. The precision of prevalence estimates can be heightened by summative analyses of the data collected around the world. To that end, we conducted a three-level mixed-effects meta-analysis. A systematic search of the Web of Science, PubMed, EMBASE, and PsycINFO databases from 2000 up to 13 July 2020 was performed, and reference lists of previous reviews and existing databases of prevalence studies were screened. Overall, 79 studies were included in the analysis of ASD and 59–in the analysis of previously existing relevant diagnoses: 30 for Autistic Disorder (AD), 15 for Asperger Syndrome (AS), and 14 for Atypical Autism (AA) and Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS); these research reports covered the period from 1994 to 2019. Pooled prevalence estimates were 0.72% (95% CI = 0.61–0.85) for ASD, 0.25% (95% CI = 0.18–0.33) for AD, 0.13% (95% CI = 0.07–0.20) for AS, and 0.18% (95% CI = 0.10–0.28) for the combined group of AA and PDD-NOS. Estimates were higher (1) for the studies that used records-review surveillance rather than other designs; (2) in North America compared with other geographical regions; and (3) in high-income compared with lower-income countries. The highest prevalence estimates were registered in the USA. There was an increase in autism prevalence estimates over time. The prevalence was also significantly higher for children aged between 6 and 12 years compared to children under the age of 5 and over the age of 13 years.

AB - Autism spectrum disorder (ASD) is one the most disabling developmental disorders, imposing an extremely high economic burden. Obtaining as accurate prevalence estimates as possible is crucial to guide governments in planning policies for identification and intervention for individuals with ASD and their relatives. The precision of prevalence estimates can be heightened by summative analyses of the data collected around the world. To that end, we conducted a three-level mixed-effects meta-analysis. A systematic search of the Web of Science, PubMed, EMBASE, and PsycINFO databases from 2000 up to 13 July 2020 was performed, and reference lists of previous reviews and existing databases of prevalence studies were screened. Overall, 79 studies were included in the analysis of ASD and 59–in the analysis of previously existing relevant diagnoses: 30 for Autistic Disorder (AD), 15 for Asperger Syndrome (AS), and 14 for Atypical Autism (AA) and Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS); these research reports covered the period from 1994 to 2019. Pooled prevalence estimates were 0.72% (95% CI = 0.61–0.85) for ASD, 0.25% (95% CI = 0.18–0.33) for AD, 0.13% (95% CI = 0.07–0.20) for AS, and 0.18% (95% CI = 0.10–0.28) for the combined group of AA and PDD-NOS. Estimates were higher (1) for the studies that used records-review surveillance rather than other designs; (2) in North America compared with other geographical regions; and (3) in high-income compared with lower-income countries. The highest prevalence estimates were registered in the USA. There was an increase in autism prevalence estimates over time. The prevalence was also significantly higher for children aged between 6 and 12 years compared to children under the age of 5 and over the age of 13 years.

KW - autism

KW - prevalence

KW - epidemiology

KW - meta-analysis

KW - systematic review

KW - autism

KW - epidemiology

KW - meta-analysis

KW - prevalence

KW - systematic review

UR - https://www.mendeley.com/catalogue/baf4540c-fe70-3705-bf15-b125b3a2f3fb/

U2 - 10.3389/fpsyt.2023.1071181

DO - 10.3389/fpsyt.2023.1071181

M3 - Article

VL - 14

JO - Frontiers in Psychiatry

JF - Frontiers in Psychiatry

SN - 1664-0640

M1 - 1071181

ER -

ID: 103171331